These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8138660)

  • 21. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer.
    Lüfter D; Richter A; Günther S; Flath B; Akrivakis C; Geppert R; Wernecke KD; Possinger K
    Anticancer Res; 2000; 20(6D):5099-105. PubMed ID: 11326676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
    Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
    Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
    Zissimopoulos A; Matthaios D; Matthaiou E; Mantadakis E; Karaitianos I
    J BUON; 2007; 12(4):505-11. PubMed ID: 18067209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
    Vinholes J; Coleman R; Lacombe D; Rose C; Tubiana-Hulin M; Bastit P; Wildiers J; Michel J; Leonard R; Nortier J; Mignolet F; Ford J
    Br J Cancer; 1999 Apr; 80(1-2):221-8. PubMed ID: 10390000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of bone markers for detection of bone metastases in lung cancer patients.
    Alataş F; Alataş O; Metintaş M; Colak O; Erginel S; Harmanci E
    Clin Biochem; 2002 Jun; 35(4):293-6. PubMed ID: 12135691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CA 15-3 in patients with locoregional and metastatic breast carcinoma.
    Geraghty JG; Coveney EC; Sherry F; O'Higgins NJ; Duffy MJ
    Cancer; 1992 Dec; 70(12):2831-4. PubMed ID: 1451063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma.
    Stieber P; Nagel D; Ritzke C; Rössler N; Kirsch CM; Eiermann W; Fateh-Moghadam A
    Eur J Clin Chem Clin Biochem; 1992 Dec; 30(12):809-14. PubMed ID: 1489855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
    Horobin JM; Browning MC; McFarlane NP; Smith G; Preece PE; Wood RA; Cuschieri A
    J R Coll Surg Edinb; 1991 Aug; 36(4):219-21. PubMed ID: 1941734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CA-549 serum levels in breast cancer monitoring.
    Zamagni C; Martoni A; Cacciari N; Bellanova B; Vecchi F; Pannuti F
    Int J Biol Markers; 1992; 7(4):217-21. PubMed ID: 1491176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
    van Dalen A
    Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
    Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
    Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
    Colomer R; Ruibal A; Salvador L
    Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnosis of skeletal metastases by serum tumor markers].
    Shinozaki T; Chigira M
    Nihon Seikeigeka Gakkai Zasshi; 1991 Aug; 65(8):441-6. PubMed ID: 1720162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
    Zulauf N; Brüggmann D; Groneberg D; Oremek GM
    Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
    Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
    Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
    Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
    Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?
    Jäger W; Kissing A; Cilaci S; Melsheimer R; Lang N
    Br J Cancer; 1994 Sep; 70(3):493-5. PubMed ID: 8080736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
    Gielen F; Dequeker J; Drochmans A; Wildiers J; Merlevede M
    Br J Cancer; 1976 Sep; 34(3):279-85. PubMed ID: 974001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radium-223 dichloride therapy in breast cancer with osseous metastases.
    Takalkar A; Paryani B; Adams S; Subbiah V
    BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26581701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
    Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
    Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.